Contextualising the developability risk of antibodies with lambda light chains using enhanced therapeutic antibody profiling.

ABSTRACT: Antibodies with lambda light chains (λ-antibodies) are generally considered to be less developable than those with kappa light chains (κ-antibodies). Though this hypothesis has not been formally established, it has led to substantial systematic biases in drug discovery pipelines and thus contributed to kappa dominance amongst clinical-stage therapeutics. However, the identification of increasing numbers of epitopes preferentially engaged by λ-antibodies shows there is a functional cost to neglecting to consider them as potential lead candidates. Here, we update our Therapeutic Antibody Profiler (TAP) tool to use the latest data and machine learning-based structure prediction, and apply it to evaluate developability risk profiles for κ-antibodies and λ-antibodies based on their surface phys

SUBMITTER: Raybould MIJ 

PROVIDER: S-EPMC10774428 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature